Actor portrayal.
NOW APPROVED FOR THE TREATMENT OF PRURIGO NODULARIS
Itch relief like that
Relieves itch fast,
with skin healing that lasts1
A novel, IL-31RA—targeted biologic that delivers itch relief as soon as 48 hours,* and helps block the urge to scratch, so patients can experience skin healing that lasts1,2
PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (OLYMPIA 2) post-hoc descriptive analysis of daily PP-NRS improvement. Significant improvement was achieved at 48 hours (13% vs 3%, P<0.02).1,2
Unique Mechanism of Action2
NEMLUVIO® is the first and only biologic to directly target IL-31RA–blocking signaling that
drives itch, inflammation, skin barrier dysfunction, and fibrosis2
Fast Itch Relief1
Significant relief† at Week 16 for 49% of patients taking NEMLUVIO vs 16% with placebo,‡ with itch relief as soon as 48 hours1,2§
Lasting Skin Healing1
38% of patients taking NEMLUVIO achieved clear (IGA 0) or almost clear (IGA 1) skin by Week 16 vs 11% with placebo,|| while 83% of patients had >75% healed nodules with over a year of treatment1,2¶
Favorable Safety Profile2
NEMLUVIO offers a favorable safety profile and requires no preliminary lab
evaluations or ongoing lab monitoring2
Q4W Dosing From the Start2,3
NEMLUVIO offers the convenience of less frequent dosing compared to the other biologic for PN2,3
Your patient’s real-time navigation partner to help guide them to success
GPS (Galderma Patient Services) for NEMLUVIO™ offers:
- Help navigating coverage, access to assistance programs, and adherence support
- Nursing support for injection training and product education
For any questions or to learn how to enroll in GPS for NEMLUVIO, please call 1-855-NEMLUVIO, 8:00 AM – 8:00 PM ET, Monday–Friday
Sign up now for more information about NEMLUVIO and PN
PP-NRS response defined as ≥4-point improvement from baseline.2
Data shown from OLYMPIA 2; in OLYMPIA 1, 56% of patients achieved significant itch relief vs 16% for placebo.2
Data from Phase 3 clinical study (OLYMPIA 2) post-hoc descriptive analysis of daily PP-NRS improvement. Significant improvement was achieved at 48 hours (13% vs 3% with placebo).1
Data shown from OLYMPIA 2. For OLYMPIA 1, 26% of patients taking NEMLUVIO achieved IGA 0 or 1 at Week 16 vs 7% with placebo.2
Data based on interim analysis from OLYMPIA Long-Term Extension.1
IGA=Investigator Global Assessment; IL-31RA=interleukin-31 receptor alpha; PN=prurigo nodularis; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks.
References: 1. Galderma Laboratories, L.P.; data on file. 2. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 3. DUPIXENT. Prescribing information. Sanofi Genzyme; 2024. 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SIR.202699; October 2023.